Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2015

01-04-2015 | Bone and Soft Tissue Sarcomas

Experience of Pediatric Osteosarcoma of the Extremity at a Single Institution in Taiwan: Prognostic Factors and Impact on Survival

Authors: Giun-Yi Hung, MD, Hsiu-Ju Yen, MD, Chueh-Chuan Yen, MD, PhD, Wei-Ming Chen, MD, Paul Chih-Hsueh Chen, MD, Hung-Ta Hondar Wu, MD, Hong-Jen Chiou, MD, Wan-Hui Chang, MS, Hsiu-E Hsu, BN

Published in: Annals of Surgical Oncology | Issue 4/2015

Login to get access

Abstract

Purpose

To identify the prognostic factors and evaluate the impact of chemotherapy regimens on the outcomes of pediatric osteosarcoma of the extremities.

Methods

Patients younger than 18 years and diagnosed with high-grade osteosarcoma of the extremities during the period between January 2004 and December 2011 were included for retrospective analysis. Demographic characteristics and tumor features were compared between nonmetastatic and metastatic patients. Univariate analyses of overall survival (OS) and progression-free survival (PFS) were performed to evaluate the efficacy of various chemotherapy regimens.

Results

A total of 74 patients (58 with nonmetastatic and 16 with metastatic disease) were enrolled and treated with three protocols consisting of various cycles of high-dose methotrexate, adriamycin (doxorubicin), cisplatin, and high-dose ifosfamide (MACI regimens) during the 8-year study period. Presence of metastasis was inversely correlated with OS and PFS. Alkaline phosphatase levels at diagnosis and histologic response to preoperative chemotherapy were correlated with OS. Tumor size was correlated with PFS. The 5-year OS and PFS were 77 and 70 % for all patients, and 90.4 and 83.3 % for those with nonmetastatic osteosarcoma; and the rates were both 25 % in those with metastatic osteosarcoma. The chemotherapy regimens increased good response rates by 30 % and survival rates by 20 % compared to the outcomes in patients treated before 2004.

Conclusions

Poor prognostic factors for osteosarcoma in pediatric patients were identified under homogeneous surgical and chemotherapy schemes. The four-drug regimens consisting of MACI contributed to the remarkably increased good response rates and consequent improvement in the survival rates.
Literature
1.
Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845–52.CrossRefPubMed
2.
Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival: a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:633–8.CrossRefPubMed
3.
Janeway KA, Barkauskas DA, Krailo MD, et al. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children’s Oncology Group. Cancer. 2012;118:4597–605.CrossRefPubMedCentralPubMed
4.
Petrilli AS, de Camargo B, Filho VO, et al. Results of the Brazilian Osteosarcoma Treatment Group studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006;24:1161–8.CrossRefPubMed
5.
Min D, Lin F, Shen Z, et al. Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy. Asia Pac J Clin Oncol. 2013;9:71–9.CrossRefPubMed
6.
Durnali A, Alkis N, Cangur S, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30:624.CrossRefPubMed
7.
Wu PK, Chen WM, Lee OK, et al. The prognosis for patients with osteosarcoma who have received prior manipulative therapy. J Bone Joint Surg Br. 2010;92:1580–5.CrossRefPubMed
8.
Lin MT, Lin KH, Lin DT, et al. Unstratified chemotherapy for non-metastatic osteosarcoma of the extremities in children. J Formos Med Assoc. 2003;102:387–93.PubMed
9.
Ministry of the Interior, Statistics Department. Monthly bulletin of interior statistics—1.1 Number of Villages, Neighborhoods, Households and Resident, 1.6 Resident Population by 5-Year, 10-Year Age Group, 1.11 Resident Population by Single Year of Age. Taipei City, Taiwan: Ministry of the Interior, Statistics Department; 2013. http://​sowf.​moi.​gov.​tw/​stat/​month/​elist.​htm. Accessed 5 April 2013.
10.
Hung GY, Horng JL, Lee YS, Yen HJ, Chen CC, Lee CY. Cancer incidence patterns among children and adolescents in Taiwan from 1995 to 2009: a population-based study. Cancer. 2014. doi:10.​1002/​cncr.​28903.
11.
Hung GY, Horng JL, Yen HJ, et al. Incidence patterns of primary bone cancer in Taiwan (2003–2010): a population-based study. Ann Surg Oncol. 2014;21:2490–8.CrossRefPubMedCentralPubMed
12.
Chen WM, Wu PK, Chen CF, et al. High-grade osteosarcoma treated with hemicortical resection and biological reconstruction. J Surg Oncol. 2012;105:825–9.CrossRefPubMed
13.
Chen WM, Chen TH, Huang CK, et al. Treatment of malignant bone tumours by extracorporeally irradiated autograft-prosthetic composite arthroplasty. J Bone Joint Surg Br. 2002;84:1156–61.CrossRefPubMed
14.
Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–61.CrossRefPubMed
15.
Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.CrossRefPubMed
16.
Hsieh MY, Hung GY, Yen HJ, et al. Osteosarcoma in preadolescent patients: experience in a single institute in Taiwan. J Chin Med Assoc. 2009;72:455–61.CrossRefPubMed
17.
Wang TI, Wu PK, Chen CF, et al. The prognosis of patients with primary osteosarcoma who have undergone unplanned therapy. Jpn J Clin Oncol. 2011;41:1244–50.CrossRefPubMed
18.
Poon KB, Chien SH, Lin GT, Wang GJ. Impact of national health insurance on the survival rate of patients with osteosarcoma in Taiwan: review of 74 patients. Kaohsiung J Med Sci. 2004;20:230–4.CrossRefPubMed
19.
Chiu TJ, Wang JW, Chen YJ, Tang Y, Huang CH. Intraarterial cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan. Chang Gung Med J. 2009;32:72–80.PubMed
20.
Lin F, Wang Q, Yu W, et al. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol. 2011;7:270–5.CrossRefPubMed
21.
Iwamoto Y, Tanaka K, Isu K, et al. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci. 2009;14:397–404.CrossRefPubMed
22.
Kudawara I, Aoki Y, Ueda T, et al. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother. 2013;25:41–8.CrossRefPubMed
23.
Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer. 2009;115:5339–48.CrossRefPubMedCentralPubMed
Metadata
Title
Experience of Pediatric Osteosarcoma of the Extremity at a Single Institution in Taiwan: Prognostic Factors and Impact on Survival
Authors
Giun-Yi Hung, MD
Hsiu-Ju Yen, MD
Chueh-Chuan Yen, MD, PhD
Wei-Ming Chen, MD
Paul Chih-Hsueh Chen, MD
Hung-Ta Hondar Wu, MD
Hong-Jen Chiou, MD
Wan-Hui Chang, MS
Hsiu-E Hsu, BN
Publication date
01-04-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 4/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4154-z

Other articles of this Issue 4/2015

Annals of Surgical Oncology 4/2015 Go to the issue

Pancreatic Tumors

Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

Healthcare Policy and Outcomes

Development and Assessment of Memorial Sloan Kettering Cancer Center’s Surgical Secondary Events Grading System

Gynecologic Oncology

Occult Invasive Cervical Cancer Found After Inadvertent Simple Hysterectomy: Is the Ideal Management: Systematic Parametrectomy With or Without Radiotherapy or Radiotherapy Only?

Thoracic Oncology

Long-Term Outcomes After Thoracoscopic Resection of Stage I and II Thymoma: A Propensity-Matched Study

Urologic Oncology

Prognostic Significance of Time to Prostate-Specific Antigen (PSA) Nadir and Its Relationship to Survival Beyond Time to PSA Nadir for Prostate Cancer Patients With Bone Metastases After Primary Androgen Deprivation Therapy

Urologic Oncology

Prognostic Significance of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma is Influenced by Tumor Location